Ursula A. Matulonis

Ursula Matulonis is Chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute and holds the Brock-Wilson Family Chair. She is a leading clinical investigator in the treatment of ovarian cancer, with particular expertise in BRCA-associated ovarian cancer, PARP inhibitor therapy, and novel targeted agents. Her laboratory and clinical work has contributed substantially to defining the clinical utility of rucaparib in BRCA-mutated ovarian cancer through participation in the ARIEL clinical trial program. Matulonis has led early-phase clinical trials exploring multiple novel targets in ovarian cancer, including folate receptor alpha (FRα)-directed therapies such as mirvetuximab soravtansine (an antibody-drug conjugate), which received FDA approval for FRα-positive, platinum-resistant ovarian cancer. Her translational research program bridges genomic analysis of tumor specimens with clinical outcome data, enabling predictive biomarker discovery for emerging therapeutics. At Dana-Farber, she has built a comprehensive gynecologic oncology program integrating standard-of-care treatment, investigational studies, and translational science. She is a frequent invited speaker at major oncology meetings, an active contributor to clinical practice guidelines, and a mentor for physician-scientists in the field. Her work has meaningfully expanded therapeutic options for patients with both newly diagnosed and recurrent ovarian cancer.